lower target see teva manag favor
opioid litig one biggest specialti pharma story-lin appar
end sight investor focu high visibl low contribut high volatil
face near constant headlin visibl remain hurdl think import lay
know report provid compil analysi
introduc new updat framework think potenti opioid liabil exposur see exhibit
result analysi increasingli cautiou outlook
lower price target time increment confid
teva abil withstand litig said potenti margin error high
continu updat refin estim go forward inform becom avail
lower price target price target
opioid liabil estim doubl billion billion assum
paid year impli major go toward liabil payment
forese futur liabil estim actual decreas margin
million million recent lower growth forecast make liabil meaning
comparison contrast although rais liabil estim teva billion
billion less concern given compani size growth profil favorit name
within gener group liabil estim declin billion million
expect stock continu grind higher continu disencumb sector headlin
might process play bull case side work toward global settlement
bind major plaintiff provid compani cash flow certainti preced
per legal expert mdl litig gener entail bellweth trial help inform
negoti strength typic lead global settlement one opioid bellweth trial
complet date jnj/ok mdl track one trial set begin next month state
trial docket resolut could within sight bear case opioid litig far
typic sheer number varieti plaintiff preclud global settlement bankruptci
becom real possibl compani plaintiff chase solvent bystand expect
suspect ultim outcom lie somewher two scenario expect
bankruptci among coverag would also rule multi-year process
focus go forward primari near-term focu mdl track one
bellweth trial schedul begin sever plaintiff alreadi settl
presum could announc trial ii progress toward potenti global
settlement recent negoti class certif ohio mdl lay groundwork
comprehens settlement although challeng get state board deadlin
local govern opt negoti class iii addit state trial
docket first awar washington state trial schedul begin
purdu said somewhat unclear trial go forward wake
price prior trade day market close estimate unless otherwis note
valu usd unless otherwis note
tabl content
background opioid litig who expos
stand litig process
two-step framework provid logic way think opioid liabil
step alloc liabil cover compani
re-visit price target make chang amneal endo
watch next
chart announc propos settlement
potenti analogu tobacco asbesto vioxx
recent compani commentari amneal endo teva emphasi
chang price target reflect updat price target framework
background opioid litig who expos
root us opioid epidem date back opioid began
prescrib chronic pain increas frequenc number opioid prescript
peak number drug overdos death continu rise reach
respons larg number state local govern among
other su varieti industri player includ drug manufactur distributor
pharmaci seek assign blame crisi claim vari gener alleg
defend engag improp market and/or distribut opioid product
plaintiff seek combin damag injunct relief and/or abat
focu report sole drug manufactur particularli respect
plaintiff cast wide net opioid-produc drug manufactur
su extent among cover name includ amneal allergan assertio
endo teva said opioid litig exposur vari wide compani
depend number type opioid product sold among factor gener
greatest risk lie brand side due activ promot stop
gener drug manufactur su exhibit provid summari opioid exposur
compani base sec file public commentari
exhibit summari opioid exposur sec disclosur cover compani
compani data iqvia factset price
companytickermarket cap opioid case pendingnot product potenti exposureupcom trial opana er gener opioidsfeder mdllargest opioid product gener oxymorphon amneal activ promot norcofeder mdlallegan indemnifi teva liabil aris legaci actavi gener per lazandafeder mdlclaim gener limit time period assertio/depom sold promot opioid opana er percocet brand gener opioidsfeder mdl certain state case schedul trial begin lawsuit file local govern nativ american tribe consolid opioidsfeder mdlrel littl disclos opioid litig involv fentora gener opioid anda distribut businessfeder mdl certain state case schedul trial begin settl state oklahoma million first case go trial specialti pharma opioid primer new framework
stand litig process
opioid litig remain earli stage sever case move forward
quickli includ oklahoma state trial ohio multidistrict litig mdl refer
exhibit summari notabl develop accord legal expert larg
complex litig usual follow typic pattern bellweth trial come first
usual around help determin valu suit establish win/loss
record inform hand parti typic abl hammer global
settlement agreement bind plaintiff even pattern hold true opioid
still long way go one bellweth trial complet date
oklahoma/johnson johnson overal litig landscap arguabl much
complex past analogu litig unfold sever pattern emerg
discuss along potenti implic
defend demonstr procliv settl mani potenti
reason compani would prefer settl rather take chanc court
includ risk larg advers judgment take million decis
johnson johnson oklahoma exampl effect reduc number
bellweth trial could prolong ultim resolut said mani
upcom opportun bellweth trial start mdl track one case
schedul begin octob expect follow number
progress made toward global settlement plaintiff
demonstr willing play along recent certif negoti class
ohio mdl clearest step yet toward comprehens resolut provid
mechan public entiti negoti settlement agreement
set name defend includ endo teva howev notabl exclud
state sever type plaintiff hospit union individu etc unless
substanti plaintiff brought board uncertainti like linger
bankruptci emerg last resort thu far two compani insi purdu
declar bankruptci result opioid litig would argu
compani outlier due over-reli opioid sale among factor
expect cover compani face similar fate
said threat bankruptci could serv power tool help bring plaintiff
exhibit summari recent opioid litig develop key upcom mileston
compani data us district court northern district ohio
two-step framework provid logic way think opioid liabil
develop framework incorpor recent settlement factor
help think estim opioid manufactur liabil imposs estim
ultim opioid liabil one compani aggreg degre certainti
well case pend simpli mani unknown variabl instead
made best estim base inform hand updat go
forward data point becom avail use two-step process first estim
overal opioid manufactur liabil use oklahoma state trial ohio mdl track one
case analogu second alloc liabil cover compani base
opioid market share factor full analysi laid
estim total opioid manufactur liabil billion use oklahoma state trial
ohio mdl track one case analogu two advanc case
multipl settlement agreement reach one trial decis case oklahoma
consid settlement non-manufactur mckesson/west virginia
tent agreement analysi includ purdu respect settlement
oklahoma attempt extrapol liabil associ subsequ
bankruptci file billion liabil estim repres simpl averag
separ analys oklahoma billion ohio mdl billion
analysi oklahoma state case impli total liabil billion see full
analysi exhibit first state opioid trial conduct date
involv three defend purdu teva johnson johnson purdu teva
elect settl trial began johnson johnson took chanc court
calcul impli liabil follow
determin total compens total compens oklahoma million
consist million purdue/teva settlement million
trial decis johnson johnson purpos analysi assum
number final account potenti changes/revers upon appeal
extrapol base rel size/opioid preval oklahoma account
us popul dispens opioid pill yield blend averag
simpl extrapol impli total unadjust liabil billion
market share adjust normal would made adjust
account defend market share opioid sale mdl howev
oklahoma author hold compani jointli sever liabl therefor
assum million comprehens
jurisdict adjust assum liabil split state local/oth
plaintiff result upward liabil adjust billion
qualit adjust appli discount result liabil estim
account two factor first opioid case go trial assum
purdu teva paid premium settl earli ii judg case
elect politician may influenc trial outcom arguabl
subject assumpt impli liabil would much higher without
adjust believ appropri base circumst
exhibit extrapol liabil oklahoma state opioid trial
companydateoutcometot valuebrand opioid share gx opioid share process could run us opioid washington pain pill liabil bmarket share assum compens comprehens dueto joint sever liabilityadjust market djurisdict liabil split state/localadjust fqualit earli settlement premium politicalpremium elect judg extrapol liabil specialti pharma opioid primer new framework
analysi ohio mdl track one case impli total liabil billion see
full analysi exhibit ohio mdl encompass opioid case file
feder jurisdict certain case select bellweth trial includ
design track one case trial schedul begin octob
howev sever defend reach settlement agreement ahead trial
serv basi analysi
determin total compens date three defend endo allergan
reach settlement agreement total million valu
extrapol base rel size/opioid preval settlement reach
cuyahoga summit counti ohio collect account
us popul dispens opioid pill simpl extrapol yield total
unadjust liabil billion
market share adjust endo allergan collect account
brand opioid share gener opioid share appli weight
brand/gener yield weight averag market share impli total
liabil billion extrapol addit manufactur
jurisdict adjust assum liabil split state local/oth
plaintiff result upward liabil adjust billion
qualit adjust oklahoma appli discount
impli liabil account earli settlement premium multipl reason
defend might want pay settl earli includ neg attent
associ trial litig cost avoid
exhibit extrapol liabil mdl track one case
companydateoutcometot valuebrand opioid share gx opioid share us opioid washington pain pill liabil bmarket share appli weight brand/gx liabilityadjust market djurisdict liabil split state/localadjust fqualit earli settlement premiumextrapol liabil specialti pharma opioid primer new framework
step alloc liabil cover compani
tri keep part analysi simpl possibl make
appropri adjust necessari multipl factor could dictat
much individu manufactur ultim pay limit analysi three
opioid market share ii abil pay iii culpabl last factor simpli refer
whether compani activ market opioid lawyer take
posit actual malfeas walk factor provid
result analysi exhibit
alloc liabil base estim brand gener opioid market share
base iqvia sale data august juli adjust known chang
sale trend earlier period exampl adjust teva brand market
share upward reflect higher sale actiq fentora prior year
assum brand opioid account total liabil gener opioid
account remain
adjust abil pay per legal expert impact potenti bankruptci
broader healthcar system like consider settlement discuss
purdu bankruptci could play well compani may differ
anticip bankruptci among coverag instead assum cash
payment stagger year cap free cash flow
endo compani among coverag limit reach result
discount assum shortfal made payment kind
appli culpabl adjust appli addit liabil discount
compani whose opioid exposur limit gener drug appli
amneal rational harder plaintiff prove
malfeas compani activ promot opioid
exhibit estim total opioid liabil compani
note estim opioid liabil assertio due rel number case finit period market opioid product
new opioid liabil estim compar prior estim exhibit provid
comparison biggest chang come respect endo
doubl liabil estim billion also increas liabil estim
teva albeit lower amount opposit true lower
estim account compani gener opioid exposur introduc liabil
estim allergan first time less billion overli meaning
compani
companybrand opioid sharegx opioid sharebrand opioid liabil opioid liabil liability pay discountculp discountadjust cash specialti pharma opioid primer new framework
exhibit comparison prior revis opioid liabil estim compani
could miss one question receiv investor
happen enough money go around mani opioid manufactur strain
balanc sheet begin limit capac take signific liabil risk
set search solvent bystand featur asbesto litig
earli occur compani rel limit opioid exposur could
find face outsiz liabil especi jurisdict subject joint sever
liabil difficult imposs model someth consid
also attempt quantifi liabil associ non-manufactur
distributor pharmaci mani data point draw
area expertis assum liabil attribut non-manufactur would
addit estim manufactur liabil
also poll investor gaug buysid expect around total opioid liabil
endo teva result shown exhibit surprisingli expect vari
wide investor gener attribut slightli higher liabil teva rel endo
analysi impli similar level liabil compani full result
investor survey see report sentiment survey closer look posit
exhibit poll investor estim endo teva total ultim opioid liabil
re-visit price target make chang amneal endo
revisit price target reflect updat opioid liabil estim
case allergan price target deal relat chang necessari
base rel manag liabil estim amneal endo teva
updat gener price target framework incorpor new opioid liabil
assumpt continu use blend adjust price-to-earnings ev/ebitda multipl
determin valuat ev/ebitda incorpor opioid liabil estim
directli within capit structur updat assumpt price target shown
result chang lower amneal price target
endo price target teva price target remain unchang
amneal opioid liabil estim littl chang lower growth
forecast make liabil signific comparison endo increas
opioid liabil estim meaning direct impact price target
despit increment neg outlook leav rate amneal
endo unchang sector perform believ opioid liabil risk alreadi
reflect current stock price
exhibit updat price target framework chart amneal endo teva
compani data factset price close capit market analysi
watch next
next major mileston ohio mdl track one trial schedul begin octob
read-through import would second bellweth trial
behind oklahoma state case also number addit state trial come next
year includ washington februari california april remain seen
purdu recent bankruptci file influenc trial especi like washington
purdu sole name defend moreov could see addit manufactur
settlement agreement time especi ahead mdl track one trial
also monitor progress toward potenti global settlement
watch ohio mdl recent certifi negoti class potenti lay
price-to-earnings troughev/ebitda averagetrack record governancegrowth outlook delev quicklyp cash flow visibilityfranchis risk litig price-to-earnings price-to-earnings adjustmentev/ebitda p/eev/ebitdashar pricemarket cap net debtenterpris valueopioid valuationestim net leverag ex opioid gener companyhistoricaladjust factor /- forecast ev/ebitdadebt ebitdaest specialti pharma opioid primer new framework
groundwork comprehens settlement deadlin novemb
class member opt otherwis includ within class
noth negoti class forc settlement agreement occur
intent laid court document clearli encourag final continu
monitor happen purdu follow recent bankruptci file could
implic cover compani even pursu similar path
chart announc propos settlement
includ manufactur non-manufactur defend announc
propos settlement
exhibit summari announc propos opioid litig settlement
companyplaintiff datetypetot valu agreement follow report purdu consid bankruptci protectionmckessonwest million payment year addit million per year next five consist one-tim cash paymentamerisourcebergen mckessongroup state propos report bloomberg unconfirm group reportedli counter demand billionendocuyahoga summit counti mdl track one case includ million cash million free drugsjohnson johnson appeal could extend final decis summit counti mdl track one casesmallinckrodtcuyahoga summit counti mdl track one case includ million cash million donat local gov ts state declar bankruptci part deal number state remain oppos specialti pharma opioid primer new framework
potenti analogu tobacco asbesto vioxx
summar sever potenti analogu exhibit cite
legal expert import caveat signific differ
case opioid read-through may limit
exhibit summari potenti opioid litig analogu
compani data expert takeaway public health law center tobacco litig nation bureau econom research asbesto litig
litigationdatebackgroundtot valuesimilaritiesdifferencestobacco master settlement agreement reach us cigarett manufactur state among other compens cost associ smoking-rel ill death juli billion paid settl state annual payment made perpetu larg number plaintiff signific public health implicationscigarett social util approv fda tobacco compani deeper pocket opioid manufacturersasbesto presentasbesto use extens construct use much centuri health risk becom wide known lead flood lawsuitsestim eventu cost asbesto litig rang high billion billiondamag done much higher plaintiff could pay formost lawsuit consist person injuri claimsvioxx approv fda new treatment pain becam blockbust product recal market shown increas risk heart attack strokemor billion consist billion settl remain product-li lawsuit anoth million settl feder class action secur lawsuit pharmaceut pain product led mani deathsvioxx sold one compani merck direct link injuri vioxx opioid order magnitud larger specialti pharma opioid primer new framework
re-publish equiti sensit chart emphas volatil stay
exhibit high leverag contribut thin equiti slice fuel volatil across group
recent compani commentari amneal endo teva emphasi
amneal amneal perspect look risk
mention certainli opioid standpoint particip mani trial
start think import recogn never detail
opioid product simpli gener substitut exist market
market detail brand product
think import distinct creat market basic provid
gener model provid substitut market suppli product
approv distributor wholesal manufactur quota
alloc us feder govern think import distinct
alway rememb think potenti risk opioid standpoint
compani like
endo think weve said term opioid focu alway
global settlement team alway work hard never go take
anyth tabl someth appropri would consid cours
absent someth materi need focus potenti mdl trial dont
know time-frame everybodi know octob there realli
materi updat respect mdl realli oklahoma
teva let clear accrual relat
million accrual relat mainli opioid million settlement
oklahoma base settlement oklahoma pure
technic account perspect settl one case show
disposit least consid settlement went thorough process
tri normal first oklahoma settlement first one usual
premium attach see case rang
possibl could term futur settlement pretti wide rang
happen term account rang point rang
like know point enough
inform base current situat know go go end book
low-end rang done
chang price target reflect updat price target framework
exhibit summari price target chang
price target base equal price-to-earnings ev/ebitda
multipl appli estim use target multipl
respect result gener valuat framework taken
trough price-to-earnings valuat histor averag ev/ebitda valuat made adjust
base company-specif attribut ev/ebitda incorpor opioid liabil
estim within capit structur impli return price target support
price target base equal price-to-earnings ev/ebitda
use target multipl respect result
gener valuat framework taken trough price-to-earnings valuat histor
averag valuat made adjust base company-specif attribut
ev/ebitda incorpor opioid liabil estim within capit structur
impli return price target support sector perform rate
exhibit allergan
allergan incom gener us special total revenu guid billioncost good total gross profit guid guid guid billionoper incom reflect amort add-back per gener reportingoth incom expens guid million interest teva dividend onward interest reflect debt pay incom expens incom tax provis incom guid incom ep adjust guid dilut share guid million sharesdividend per grow annuallyebitda ebitda analysi revenu net gross guid guid guid billionoper guid incom margin exhibit amneal
 incom revenu half weight primarili gener launchescost gross profit guid adj gross guid guid revenueoper incom annual paydown leverag target high low incom tax incom guid tax ratenet incom pro-forma guid dilut guid million sharesebitda margin gross specialti pharma gross margin guid adj gross guid guid revenueoper expens guid tax ratenet incom margin analysi specialti total revenu oper net guid million exhibit endo
endo incom brand us gener total revenu guid billion weightedcost gross profit guid lower cost vs opex revoper incom interest income- interest guid million incom expens net incom tax incom guid interest- net incom ep adjust guid weighted dilut share guid millionebitda guid billion weight ebitda analysi brand gener revenu reflect ramp spend launch cch/celluliteadjust gross guid guid incom margin high teen adj eff tax mid opex revenue exhibit mylan
 incom guid hsd growth north guid msd growth eurest guid msd growth rowoth gener total revenu guid billioncost gross profit guid guid total revenuessg guid total revenuesoper incom incom incom tax incom guid incom prefer dividend adjust net guid billionep adjust guid dilut share guid million guid billion growth ebitda analysi margin guid guid total guid total revenuesoper expens guid net incom exhibit teva
teva incom segment restat effect growth total revenu guid billioncost gross profit gener incom guid billionoth incom incom tax provis incom guid tax ratenet incom add-back prefer adjust net ep pro-forma guid dilut share guid million sharesebitda guid billion ebitda expens guid tax rateadjust net incom analysi net specialti pharma opioid primer new framework
analyst respons prepar research report receiv compens base upon variou factor includ
total revenu member compani capit market affili portion gener
invest bank activ member compani capit market affili
pleas note current conflict disclosur may differ public date set forth
report access current conflict disclosur client refer http //www rbccm com/gldisclosure/publicweb/
send request cm research publish bay street royal bank plaza
capit market llc make market secur allergan public limit compani
capit market provid allergan public limit compani non-invest bank securities-rel servic
past month
capit market llc make market secur inc
member compani capit market one affili receiv compens product servic
invest bank servic inc past month time member compani
capit market one affili provid non-secur servic inc
capit market provid inc non-secur servic past month
member compani capit market one affili manag co-manag public offer secur endo
plc past month
member compani capit market one affili receiv compens invest bank servic
plc past month
capit market llc make market secur plc
dominion secur inc make market secur plc
member compani capit market one affili receiv compens product servic
invest bank servic plc past month time member compani
capit market one affili provid non-secur servic plc
capit market current provid plc non-secur servic
capit market provid plc invest bank servic past month
capit market llc make market secur
capit market llc make market secur teva pharmaceut industri limit
member compani capit market one affili receiv compens product servic
invest bank servic teva pharmaceut industri limit past month time member
compani capit market one affili provid non-secur servic teva pharmaceut industri limit
capit market current provid teva pharmaceut industri limit non-secur servic
explan capit market equiti rate system
analyst sector univers compani analyst provid research coverag accordingli rate assign
particular stock repres sole analyst view stock perform next month rel
top pick tp repres analyst best idea sector expect provid signific absolut total return month
favor risk-reward ratio
outperform expect materi outperform sector averag month
sector perform sp return expect line sector averag month
under-perform return expect materi sector averag month
restrict polici preclud certain type commun includ invest recommend
act advisor certain merger strateg transact certain circumst
rate nr rate price target estim remov due applic legal regulatori polici constraint
may includ capit market act advisori capac involv compani
specul risk rate reflect secur lower level financi oper predict illiquid share trade volum
high balanc sheet leverag limit oper histori result higher expect financi and/or stock price volatil
distribut rate
purpos rate distribut regulatori rule requir member firm assign rate one three rate categori
 buy hold/neutr sell regardless firm rate categori although capit market rate top pick/
outperform sector perform under-perform close correspond buy hold/neutr sell respect mean
rate determin rel basi
distribut rate
rate price target histori allergan public limit compani agn us usd
tp top pick outperform sp sector perform under-perform restrict initi research coverag discontinu research coverag
nr rate na avail rl recommend list rl refer date secur place recommend list rl refer date
secur remov recommend list rtg rate
creat bluematrix
rate price target histori inc us usd
tp top pick outperform sp sector perform under-perform restrict initi research coverag discontinu research coverag
nr rate na avail rl recommend list rl refer date secur place recommend list rl refer date
secur remov recommend list rtg rate
creat bluematrix
rate price target histori plc us usd
tp top pick outperform sp sector perform under-perform restrict initi research coverag discontinu research coverag
nr rate na avail rl recommend list rl refer date secur place recommend list rl refer date
secur remov recommend list rtg rate
creat bluematrix
rate price target histori mylan us usd
tp top pick outperform sp sector perform under-perform restrict initi research coverag discontinu research coverag
nr rate na avail rl recommend list rl refer date secur place recommend list rl refer date
secur remov recommend list rtg rate
creat bluematrix
rate price target histori teva pharmaceut industri limit teva us usd
tp top pick outperform sp sector perform under-perform restrict initi research coverag discontinu research coverag
nr rate na avail rl recommend list rl refer date secur place recommend list rl refer date
secur remov recommend list rtg rate
creat bluematrix
refer recommend list recommend histori chart may includ one recommend list model
portfolio maintain wealth manag one affili wealth manag recommend list includ
guid portfolio prime incom rl guid portfolio dividend growth rl guid portfolio adr rl
guid portfolio cap growth rl capit market recommend list includ strategi focu list
fundament equiti weight portfolio abbrevi rl mean date secur place
recommend list abbrevi rl mean date secur remov recommend list
equiti valuat risk
valuat method use determin risk may imped achiev price target cover compani pleas
see recent company-specif research report http //www rbcinsightresearch com send request capit
price target reflect offer cash share impli ep estim
stand-alone estim reflect single-digit ep growth forecast lack meaning near-term catalyst drive upsid
multipl reflect cautiou view stock price target impli return support sector perform rate
risk rate price target
risk price target rate includ limit inabl convert pipelin product competit key
product prove intens model activist pressur
price target base equal price-to-earnings ev/ebitda multipl appli estim use target multipl
respect result gener valuat framework taken trough price-to-earnings valuat
histor averag ev/ebitda valuat made adjust base company-specif attribut ev/ebitda
incorpor opioid liabil estim within capit structur impli return price target support sector
risk rate price target
risk price target rate includ eros base busi compar assumpt challeng drive
growth brand busi delay launch pipelin opportun
price target base equal price-to-earnings ev/ebitda use target multipl respect
result gener valuat framework taken trough price-to-earnings valuat histor averag
valuat made adjust base company-specif attribut ev/ebitda incorpor opioid liabil estim
within capit structur impli return price target support sector perform rate
risk rate price target
risk rate price target aris greater-than-expect competit key product continu eros
base busi approv pend anda opportun grow ebitda convert free
cash flow given high leverag pend cash call includ mesh litig
price target base ev/ebitda multipl appli pro-forma newco ebitda estim
modestli valuat level trade pre-deal announc sector histor averag multipl
reflect continu challeng industri impli return price target opportun upsid
support outperform rate
risk rate price target
risk rate price target includ limit delay around pipelin convers slower expect
new launch uptak impair us base busi delay upjohn deal close and/or integr issu
inopportun use cash boost leverag and/or impair sharehold valu
price target base equal price-to-earnings ev/ebitda reflect teva moder lower tax rate current leverag
price target base multipl respect reflect uniqu fundament risk current
pipelin without risk iv leverag risk heighten level price target support sector perform rate
risk rate price target
follow could lead teva realiz downsid price target rate slower expect sale ramp
ajovi austedo higher expect top-lin impact base busi aggress cost cut continu price
pressur multipl addit gener copaxon launch weak cash flow gener jeopard debt paydown
coven complianc uncertainti around potenti liabil associ opioid litig
capit market polici manag conflict interest relat invest research avail us request
access current polici client refer
send request capit market research publish bay street royal bank plaza floor south
tower toronto ontario reserv right amend supplement polici time
dissemin research short-term trade idea
capit market endeavor make reason effort provid research simultan elig client
regard local time zone oversea jurisdict capit market equiti research post proprietari websit
ensur elig client receiv coverag initi chang rate target opinion time manner addit
distribut may done sale personnel via email fax electron mean regular mail client may also
receiv research via third parti vendor capit market also provid elig client access sparc firm
proprietari insight websit via email via third-parti vendor sparc contain market color commentari regard
subject compani firm current provid equiti research coverag research analyst may time time
includ short-term trade idea research report sparc short-term trade idea offer short-term view
secur may trade base market trade event result trade opportun may avail
short-term trade idea may differ price target recommend publish research report reflect
research analyst view long-term one year prospect subject compani result differ time horizon
methodolog and/or factor thu possibl subject compani common equiti consid long-term
sector perform even under-perform might present short-term buy opportun result temporari sell pressur
market convers subject compani common equiti rate long-term outperform could consid suscept
short-term downward price correct short-term trade idea rate part rate system
firm gener intend undertak oblig maintain updat short-term trade idea short-term trade
idea may suitabl investor tailor individu investor circumst object
investor make independ decis regard secur strategi discuss herein pleas contact
invest advisor institut salesperson inform regard capit market research
list recommend compani dissemin prior period pleas click
month histori sparc view http //www rbcinsightresearch com
view express report accur reflect person view respons analyst
subject secur issuer part compens respons analyst name herein directli
indirectli relat specif recommend view express respons analyst report
global industri classif standard gic develop exclus properti servic mark inc standard poor financi servic
llc licens use neither parti involv make compil gic gic classif make express impli
warranti represent respect standard classif result obtain use thereof parti herebi expressli disclaim warranti
origin accuraci complet merchant fit particular purpos respect standard classif without limit forego
event shall affili third parti involv make compil gic gic classif liabil direct indirect special
punit consequenti damag includ lost profit even notifi possibl damag
refer herein libor libo rate libor abbrevi mean london interbank offer rate administ benchmark administr
person take administr rate
capit market busi name use certain branch subsidiari royal bank canada includ dominion secur inc
capit market llc europ limit royal bank canada hong kong branch royal bank canada sydney branch inform contain
report compil capit market sourc believ reliabl represent warranti express impli made royal
canada capit market affili person accuraci complet correct opinion estim contain
report constitut capit market judgement date report subject chang without notic provid good faith without
legal respons noth report constitut legal account tax advic individu tailor invest advic materi prepar gener
circul client prepar without regard individu financi circumst object person receiv invest
servic contain report may suitabl recommend consult independ invest advisor doubt
suitabl invest servic report offer sell solicit offer buy secur past perform guid
futur perform futur return guarante loss origin capit may occur capit market research analyst compens base
part overal profit capit market includ profit attribut invest bank revenu everi provinc canada state
 countri throughout world law regul type secur invest product may offer
resid well process result secur discuss report may elig sale jurisdict capit
market may restrict publish research report time time due regulatori restrict and/ intern complianc polici case
latest publish research report avail client may reflect recent materi chang applic industri and/or applic subject compani
capit market research report current date set forth research report report circumst
constru solicit act secur broker dealer jurisdict person compani legal permit carri busi
secur broker dealer jurisdict full extent permit law neither capit market affili person accept
liabil whatsoev direct indirect consequenti loss aris connect use report inform contain herein
matter contain document may reproduc copi mean without prior written consent capit market instanc
addit inform avail request
public approv capit market llc member finra nyse sipc regist broker-deal accept
respons report dissemin unit state recipi report regist broker-deal bank act
broker dealer capac wish inform regard effect transact secur discuss report
contact place order capit market llc
public approv dominion secur inc member iiroc canadian recipi report design institut
ontario accredit investor british columbia alberta sophist purchas quebec similar permit purchas provinc
wish inform regard effect transact secur discuss report contact place order
dominion secur inc without way limit forego accept respons report dissemin canada
public approv europ limit el author prudenti regul author regul
conduct author fca prudenti regul author connect distribut unit kingdom materi gener
distribut unit kingdom retail client defin rule fca rbcel accept respons report dissemin
unit kingdom
materi distribut germani europ limit frankfurt branch regul bundesanstalt fr finanzdienstleistungsaufsicht bafin
receiv advic australia
materi distribut australia royal bank canada sydney branch abn afsl materi prepar
gener circul take account object financi situat need recipi accordingli recipi act
materi consid appropri materi regard object financi situat need materi relat acquisit
possibl acquisit particular financi product recipi australia obtain relev disclosur document prepar respect product
